Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
- PMID:16162882
- DOI: 10.1056/NEJMoa050524
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
Erratum in
- N Engl J Med. 2005 Nov 24;353(21):2311
Abstract
Background: A substantial number of patients with rheumatoid arthritis have an inadequate or unsustained response to tumor necrosis factor alpha (TNF-alpha) inhibitors. We conducted a randomized, double-blind, phase 3 trial to evaluate the efficacy and safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis and an inadequate response to at least three months of anti-TNF-alpha therapy.
Methods: Patients with active rheumatoid arthritis and an inadequate response to anti-TNF-alpha therapy were randomly assigned in a 2:1 ratio to receive abatacept or placebo on days 1, 15, and 29 and every 28 days thereafter for 6 months, in addition to at least one disease-modifying antirheumatic drug. Patients discontinued anti-TNF-alpha therapy before randomization. The rates of American College of Rheumatology (ACR) 20 responses (indicating a clinical improvement of 20 percent or greater) and improvement in functional disability, as reflected by scores for the Health Assessment Questionnaire (HAQ) disability index, were assessed.
Results: After six months, the rates of ACR 20 responses were 50.4 percent in the abatacept group and 19.5 percent in the placebo group (P<0.001); the respective rates of ACR 50 and ACR 70 responses were also significantly higher in the abatacept group than in the placebo group (20.3 percent vs. 3.8 percent, P<0.001; and 10.2 percent vs. 1.5 percent, P=0.003). At six months, significantly more patients in the abatacept group than in the placebo group had a clinically meaningful improvement in physical function, as reflected by an improvement from baseline of at least 0.3 in the HAQ disability index (47.3 percent vs. 23.3 percent, P<0.001). The incidence of adverse events and peri-infusional adverse events was 79.5 percent and 5.0 percent, respectively, in the abatacept group and 71.4 percent and 3.0 percent, respectively, in the placebo group. The incidence of serious infections was 2.3 percent in each group.
Conclusions: Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy.
Copyright 2005 Massachusetts Medical Society.
Similar articles
- Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.Genovese MC, et al.J Rheumatol. 2012 Aug;39(8):1546-54. doi: 10.3899/jrheum.111531. Epub 2012 Jul 15.J Rheumatol. 2012.PMID:22798265Clinical Trial.
- Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.Furst DE, et al.J Rheumatol. 2003 Dec;30(12):2563-71.J Rheumatol. 2003.PMID:14719195Clinical Trial.
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group.Ruperto N, et al.Lancet. 2008 Aug 2;372(9636):383-91. doi: 10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14.Lancet. 2008.PMID:18632147Clinical Trial.
- Role of abatacept in the management of rheumatoid arthritis.Nogid A, Pham DQ.Nogid A, et al.Clin Ther. 2006 Nov;28(11):1764-78. doi: 10.1016/j.clinthera.2006.11.020.Clin Ther. 2006.PMID:17212998Review.
- Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.Guyot P, Taylor PC, Christensen R, Pericleous L, Drost P, Eijgelshoven I, Bergman G, Lebmeier M.Guyot P, et al.J Rheumatol. 2012 Jun;39(6):1198-206. doi: 10.3899/jrheum.111345. Epub 2012 Apr 15.J Rheumatol. 2012.PMID:22505698Review.
Cited by
- Optimization of current and future therapy for autoimmune diseases.Steinman L, Merrill JT, McInnes IB, Peakman M.Steinman L, et al.Nat Med. 2012 Jan 6;18(1):59-65. doi: 10.1038/nm.2625.Nat Med. 2012.PMID:22227674No abstract available.
- The problem of choice: current biologic agents and future prospects in RA.Choy EH, Kavanaugh AF, Jones SA.Choy EH, et al.Nat Rev Rheumatol. 2013 Mar;9(3):154-63. doi: 10.1038/nrrheum.2013.8. Epub 2013 Feb 19.Nat Rev Rheumatol. 2013.PMID:23419427Review.
- Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjögren's syndrome.Yin H, Nguyen CQ, Samuni Y, Uede T, Peck AB, Chiorini JA.Yin H, et al.Arthritis Res Ther. 2012 Feb 27;14(1):R40. doi: 10.1186/ar3753.Arthritis Res Ther. 2012.PMID:22369699Free PMC article.
- Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis.Mysler E, Caubet M, Lizarraga A.Mysler E, et al.Open Access Rheumatol. 2021 Jun 1;13:139-152. doi: 10.2147/OARRR.S282627. eCollection 2021.Open Access Rheumatol. 2021.PMID:34104009Free PMC article.Review.
- Decision tool to improve the quality of care in rheumatoid arthritis.Fraenkel L, Peters E, Charpentier P, Olsen B, Errante L, Schoen RT, Reyna V.Fraenkel L, et al.Arthritis Care Res (Hoboken). 2012 Jul;64(7):977-85. doi: 10.1002/acr.21657.Arthritis Care Res (Hoboken). 2012.PMID:22392766Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical